The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients

Reference

• StuppRMasonWPvan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
   PubMed Web of Science ®Google Scholar
• HicklinDJEllisLMRole of the vascular endothelial growth factor pathway in tumor growth and angiogenesisJ Clin Oncol20052351011102715585754
   PubMed Web of Science ®Google Scholar
• PlateKHScholzADumontDJTumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisitedActa Neuropathol2012124676377523143192
   PubMed Web of Science ®Google Scholar
• JainRKNormalization of tumor vasculature: an emerging concept in antiangiogenic therapyScience20053075706586215637262
   PubMed Web of Science ®Google Scholar
• BatchelorTTGerstnerEREmblemKEImproved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationProc Natl Acad Sci USA201311047190591906424190997
   PubMed Web of Science ®Google Scholar
• de GrootJFMandelJJUpdate on anti-angiogenic treatment for malignant gliomasCurr Oncol Rep201416438024510742
   PubMed Web of Science ®Google Scholar
• HanKRenMWickWProgression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trialsNeuro Oncol201416569670624335699
   PubMed Web of Science ®Google Scholar
• HenrikssonRAsklundTPoulsenHSImpact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a reviewJ Neurooncol2011104363964621468776
   PubMed Web of Science ®Google Scholar
• JakobsenJNHasselbalchBStockhausenMTLassenUPoulsenHSIrinotecan and bevacizumab in recurrent glioblastoma multiformeExpert Opin Pharmacother201112582583321385110
   PubMed Web of Science ®Google Scholar
• OlsonJJNayakLOrmondDRThe role of targeted therapies in the management of progressive glioblastoma: A systematic review and evidence-based clinical practice guidelineJ Neurooncol2014
   Google Scholar
• ChauffertBFeuvretLBonnetainFRandomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared to temozolomide-chemoradiation for unresectable glioblastoma. Final results of the TEMAVIR study from ANOCEFAnn Oncol2014
   Web of Science ®Google Scholar
• HoflandKFHansenSSorensenMNeoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II studyActa Oncol2014
   Web of Science ®Google Scholar
• LaiATranANghiemphuPLPhase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiformeJ Clin Oncol201129214214821135282
   PubMed Web of Science ®Google Scholar
• LouEPetersKBSumrallALPhase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastomaCancer Med20132218519523634286
   PubMed Web of Science ®Google Scholar
• NarayanaAGruberDKunnakkatSA clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastomaJ Neurosurg2012116234134522035272
   PubMed Web of Science ®Google Scholar
• OmuroABealKGutinPPhase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastomaClin Cancer Res Epub882014
   Web of Science ®Google Scholar
• VredenburghJJDesjardinsAReardonDAThe addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastomaClin Cancer Res201117124119412421531816
   PubMed Web of Science ®Google Scholar
• ChinotOLWickWMasonWBevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastomaN Engl J Med2014370870972224552318
   PubMed Web of Science ®Google Scholar
• GilbertMRDignamJJArmstrongTSA randomized trial of bevacizumab for newly diagnosed glioblastomaN Engl J Med2014370869970824552317
   PubMed Web of Science ®Google Scholar
• HerrlingerUSchäferNSteinbachJPSurvival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patientsJ Clin Oncol5312014325s (suppl; abstr 2042)
   Google Scholar
• FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med197128521118211864938153
   PubMed Web of Science ®Google Scholar
• SathornsumeteeSRichJNAntiangiogenic therapy in malignant glioma: promise and challengeCurr Pharm Des200713353545355818220791
   PubMed Web of Science ®Google Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer20088859260318650835
   PubMed Web of Science ®Google Scholar
• Lucio-EterovicAKPiaoYde GrootJFMediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapyClin Cancer Res200915144589459919567589
   PubMed Web of Science ®Google Scholar
• PiaoYLiangJHolmesLAcquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transitionClin Cancer Res201319164392440323804423
   PubMed Web of Science ®Google Scholar
• JainRKNormalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapyNat Med20017998798911533692
   PubMed Web of Science ®Google Scholar
• ChaeSSKamounWSFarrarCTAngiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomasClin Cancer Res201016143618362720501615
   PubMed Web of Science ®Google Scholar
• GoelSDudaDGXuLNormalization of the vasculature for treatment of cancer and other diseasesPhysiol Rev20119131071112121742796
   PubMed Web of Science ®Google Scholar
• McGeeMCHamnerJBWilliamsRFImproved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiationInt J Radiat Oncol Biol Phys20107651537154520338480
   PubMed Web of Science ®Google Scholar
• WinklerFKozinSVTongRTKinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinasesCancer Cell20046655356315607960
   PubMed Web of Science ®Google Scholar
• HamerlikPLathiaJDRasmussenRAutocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growthJ Exp Med2012209350752022393126
   PubMed Web of Science ®Google Scholar
• FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927
   PubMed Web of Science ®Google Scholar
• MichaelsenSRChristensenIJGrunnetKClinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institutionBMC Cancer20131340224004722
   PubMed Web of Science ®Google Scholar
• HegiMEDiserensACGorliaTMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med200535210997100315758010
   PubMed Web of Science ®Google Scholar
• GilbertMRWangMAldapeKDDose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trialJ Clin Oncol201331324085409124101040
   PubMed Web of Science ®Google Scholar
• BlochOSafaeeMSunMZDisseminated progression of glioblastoma after treatment with bevacizumabClin Neurol Neurosurg201311591795180123706614
   PubMed Web of Science ®Google Scholar
• ChamberlainMCRadiographic patterns of relapse in glioblastomaJ Neurooncol2011101231932321052776
   PubMed Web of Science ®Google Scholar
• PopeWBXiaQPatonVEPatterns of progression in patients with recurrent glioblastoma treated with bevacizumabNeurology201176543243721282590
   PubMed Web of Science ®Google Scholar
• de GrootJFFullerGKumarAJTumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and miceNeuro Oncol201012323324220167811
   PubMed Web of Science ®Google Scholar
• KeunenOJohanssonMOudinAAnti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastomaProc Natl Acad Sci USA201110893749375421321221
   PubMed Web of Science ®Google Scholar
• HasselbalchBEriksenJGBroholmHProspective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecanAPMIS2010118858559420666740
   PubMed Web of Science ®Google Scholar
• LaffaireJDi StefanoALChinotOAn ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomasBiomed Res Int2014201428281524804210
   PubMed Web of Science ®Google Scholar
• SathornsumeteeSCaoYMarcelloJETumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecanJ Clin Oncol200826227127818182667
   PubMed Web of Science ®Google Scholar
• DeLayMJahangiriACarbonellWSMicroarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapyClin Cancer Res201218102930294222472177
   PubMed Web of Science ®Google Scholar
• Paez-RibesMAllenEHudockJAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisCancer Cell200915322023119249680
   PubMed Web of Science ®Google Scholar
• JubbAMBrowningLCampoLExpression of vascular Notch ligands Delta-like 4 and Jagged-1 in glioblastomaHistopathology201260574074722296176
   PubMed Web of Science ®Google Scholar
• Lu-EmersonCSnuderlMKirkpatrickNDIncrease in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastomaNeuro Oncol20131581079108723828240
   PubMed Web of Science ®Google Scholar
• MurdochCMuthanaMCoffeltSBLewisCEThe role of myeloid cells in the promotion of tumour angiogenesisNat Rev Cancer20088861863118633355
   PubMed Web of Science ®Google Scholar
• LuKVBergersGMechanisms of evasive resistance to anti-VEGF therapy in glioblastomaCNS Oncol201321496523750318
   PubMedGoogle Scholar
• PiaoYLiangJHolmesLGlioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotypeNeuro Oncol201214111379139222965162
   PubMed Web of Science ®Google Scholar
• ShojaeiFWuXZhongCBv8 regulates myeloid-cell-dependent tumour angiogenesisNature2007450717182583118064003
   PubMed Web of Science ®Google Scholar
• JanbazianLKaramchandaniJDasSMouse models of glioblastoma: lessons learned and questions to be answeredJ Neurooncol201411811824522719
   PubMed Web of Science ®Google Scholar
• JahangiriADeLMMillerLMGene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistanceClin Cancer Res20131971773178323307858
   PubMed Web of Science ®Google Scholar
• LuKVChangJPParachoniakCAVEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complexCancer Cell2012221213522789536
   PubMed Web of Science ®Google Scholar
• FrancesconeRScullySBentleyBGlioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activationJ Biol Chem201228729248212483122654102
   PubMed Web of Science ®Google Scholar
• YaoXPingYLiuYVascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cellsPLoS One201383e5718823536763
   PubMed Web of Science ®Google Scholar
• LampsonLAMonoclonal antibodies in neuro-oncology: Getting past the blood-brain barrierMAbs20113215316021150307
   PubMed Web of Science ®Google Scholar
• PhillipsHSandmanTLiCCorrelation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]).)J Clin Oncol2014325 (suppl; abstr 2001)
   Google Scholar
• PhillipsHSKharbandaSChenRMolecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesisCancer Cell20069315717316530701
   PubMed Web of Science ®Google Scholar
• VerhaakRGHoadleyKAPurdomEIntegrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell20101719811020129251
   PubMed Web of Science ®Google Scholar
• WongETGautamSMalchowCBevacizumab for recurrent glioblastoma multiforme: a meta-analysisJ Natl Compr Canc Netw20119440340721464145
   PubMed Web of Science ®Google Scholar
• AndersonMDHamzaMAHessKRPuduvalliVKImplications of bevacizumab discontinuation in adults with recurrent glioblastomaNeuro Oncol201416682382824596117
   PubMed Web of Science ®Google Scholar
• ArmstrongTSWenPYGilbertMRSchiffDManagement of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumorsNeuro Oncol201214101203121422307472
   PubMed Web of Science ®Google Scholar
• MacdonaldDRCascinoTLScholdSCJrCairncrossJGResponse criteria for phase II studies of supratentorial malignant gliomaJ Clin Oncol199087127712802358840
   PubMed Web of Science ®Google Scholar
• ReardonDAGalanisEDeGrootJFClinical trial end points for high-grade glioma: the evolving landscapeNeuro Oncol201113335336121310734
   PubMed Web of Science ®Google Scholar
• WenPYMacdonaldDRReardonDAUpdated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working groupJ Clin Oncol201028111963197220231676
   PubMed Web of Science ®Google Scholar
• FinnMABlumenthalDTSalzmanKLJensenRLTransient postictal MRI changes in patients with brain tumors may mimic disease progressionSurg Neurol200767324625017320628
   PubMedGoogle Scholar
• HenegarMMMoranCJSilbergeldDLEarly postoperative magnetic resonance imaging following nonneoplastic cortical resectionJ Neurosurg19968421741798592218
   PubMed Web of Science ®Google Scholar
• KumarAJLeedsNEFullerGNMalignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatmentRadiology2000217237738411058631
   PubMed Web of Science ®Google Scholar
• UlmerSBragaTABarkerFGClinical and radiographic features of peritumoral infarction following resection of glioblastomaNeurology20066791668167017101902
   PubMed Web of Science ®Google Scholar
• BrandsmaDStalpersLTaalWSminiaPvan den BentMJClinical features, mechanisms, and management of pseudoprogression in malignant gliomasLancet Oncol20089545346118452856
   PubMed Web of Science ®Google Scholar
• ChamberlainMCGlantzMJChalmersLVanHASloanAEEarly necrosis following concurrent Temodar and radiotherapy in patients with glioblastomaJ Neurooncol2007821818316944309
   PubMed Web of Science ®Google Scholar
• de WitMCde BruinHGEijkenboomWSillevis SmittPAvan den BentMJImmediate post-radiotherapy changes in malignant glioma can mimic tumor progressionNeurology200463353553715304589
   PubMed Web of Science ®Google Scholar
• TaalWBrandsmaDde BruinHGIncidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomideCancer2008113240541018484594
   PubMed Web of Science ®Google Scholar
• HensonJWUlmerSHarrisGJBrain tumor imaging in clinical trialsAJNR Am J Neuroradiol200829341942418272557
   PubMed Web of Science ®Google Scholar
• SorensenAGBatchelorTTWenPYZhangWTJainRKResponse criteria for gliomaNat Clin Pract Oncol200851163464418711427
   PubMedGoogle Scholar
• van den BentMJVogelbaumMAWenPYMacdonaldDRChangSMEnd point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s CriteriaJ Clin Oncol200927182905290819451418
   PubMed Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJEBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin Oncol200725304722472917947719
   PubMed Web of Science ®Google Scholar
• Hygino da CruzLCJrRodriguezIDominguesRCGasparettoELSorensenAGPseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment gliomaAJNR Am J Neuroradiol201132111978198521393407
   PubMed Web of Science ®Google Scholar
• ChinotOLMacdonaldDRAbreyLEResponse assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapyCurr Neurol Neurosci Rep201313534723529375
   PubMed Web of Science ®Google Scholar
• Gallego Perez-LarrayaJLahutteMPetrirenaGResponse assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteriaNeuro Oncol201214566767322492961
   PubMed Web of Science ®Google Scholar
• ColavolpeCChinotOMetellusPFDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecanNeuro Oncol201214564965722379188
   PubMed Web of Science ®Google Scholar
• OliveroWCDulebohnSCListerJRThe use of PET in evaluating patients with primary brain tumours: is it useful?J Neurol Neurosurg Psychiatry19955822502527876865
   PubMed Web of Science ®Google Scholar
• Corroyer-DulmontAPeresEAPetitEDetection of glioblastoma response to temozolomide combined with bevacizumab based on muMRI and muPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacyNeuro Oncol2013151415623115160
   PubMed Web of Science ®Google Scholar
• NedergaardMKKristoffersenKMichaelsenSRThe Use of Longitudinal 18F-FET MicroPET Imaging to Evaluate Response to Irinotecan in Orthotopic Human Glioblastoma Multiforme XenograftsPLoS One201492e10000924918622
   PubMed Web of Science ®Google Scholar
• GalldiksNRappMStoffelsGResponse assessment of bevacizumab in patients with recurrent malignant glioma using [18F] Fluoroethyl-L-tyrosine PET in comparison to MRIEur J Nucl Med Mol Imaging2013401223323053325
   PubMed Web of Science ®Google Scholar
• BrandesAAFranceschiEGorliaTAppropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastomaEur J Cancer201248689690322119352
   PubMed Web of Science ®Google Scholar
• NordenADDrappatzJMuzikanskyAAn exploratory survival analysis of anti-angiogenic therapy for recurrent malignant gliomaJ Neurooncol200992214915519043778
   PubMed Web of Science ®Google Scholar
• TaphoornMJKleinMEvaluation of cognitive functions and quality of lifeHandb Clin Neurol201210417318322230444
   PubMedGoogle Scholar
• BosmaIVosMJHeimansJJThe course of neurocognitive functioning in high-grade glioma patientsNeuro Oncol200791536217018697
   PubMed Web of Science ®Google Scholar
• MeyersCAScheibelRSEarly detection and diagnosis of neurobehavioral disorders associated with cancer and its treatmentOncology (Williston Park)1990471151221697183
   PubMedGoogle Scholar
• de VriesMAvan LitsenburgRRHuismanJEffect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational studyHealth Qual Life Outcomes2008610319036151
   PubMed Web of Science ®Google Scholar
• LupienSJGillinCJHaugerRLWorking memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humansBehav Neurosci1999113342043010443770
   PubMed Web of Science ®Google Scholar
• YoungAHSahakianBJRobbinsTWCowenPJThe effects of chronic administration of hydrocortisone on cognitive function in normal male volunteersPsychopharmacology (Berl)1999145326026610494574
   PubMed Web of Science ®Google Scholar
• HempenCWeissEHessCFDexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects?Support Care Cancer200210432232812029432
   PubMed Web of Science ®Google Scholar
• SturdzaAMillarBABanaNThe use and toxicity of steroids in the management of patients with brain metastasesSupport Care Cancer20081691041104818256860
   PubMed Web of Science ®Google Scholar
• BoksteinFShpigelSBlumenthalDTTreatment with bevacizumab and irinotecan for recurrent high-grade glial tumorsCancer2008112102267227318327820
   PubMed Web of Science ®Google Scholar
• DesjardinsAReardonDAHerndonJEBevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomasClin Cancer Res200814217068707318981004
   PubMed Web of Science ®Google Scholar
• GuiuSTaillibertSChinotOBevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter StudyRev Neurol (Paris)20081646–758859418565358
   PubMed Web of Science ®Google Scholar
• NghiemphuPLLiuWLeeYBevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experienceNeurology200972141217122219349600
   PubMed Web of Science ®Google Scholar
• NordenADYoungGSSetayeshKBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology2008701077978718316689
   PubMed Web of Science ®Google Scholar
• BurgerPCDuboisPJScholdSCJrComputerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiformeJ Neurosurg19835821591696294260
   PubMed Web of Science ®Google Scholar
• ChangELAkyurekSAvalosTEvaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastomaInt J Radiat Oncol Biol Phys200768114415017306935
   PubMed Web of Science ®Google Scholar
• HochbergFHPruittAAssumptions in the radiotherapy of glioblastomaNeurology19803099079116252514
   PubMed Web of Science ®Google Scholar
• LevinVACraftsDCNormanDMCriteria for evaluating patients undergoing chemotherapy for malignant brain tumorsJ Neurosurg1977473329335894339
   PubMed Web of Science ®Google Scholar
• IwamotoFMAbreyLEBealKPatterns of relapse and prognosis after bevacizumab failure in recurrent glioblastomaNeurology200973151200120619822869
   PubMed Web of Science ®Google Scholar
• NarayanaAKellyPGolfinosJAntiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survivalJ Neurosurg2009110117318018834263
   PubMed Web of Science ®Google Scholar
• WickADornerNSchaferNBevacizumab does not increase the risk of remote relapse in malignant gliomaAnn Neurol201169358659221446027
   PubMed Web of Science ®Google Scholar
• SoffiettiRTrevisanEBerteroLBevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)J Neurooncol2014116353354124293233
   PubMed Web of Science ®Google Scholar
• DesjardinsAReardonDACoanABevacizumab and daily temozolomide for recurrent glioblastomaCancer201211851302131221792866
   PubMed Web of Science ®Google Scholar